Health Care

Bristol Myers to buy RayzeBio for about $4.1B

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.

Open enrollment is here: Why an HSA is worth it

Open enrollment is offered one time annually and permits most employees to review their healthcare coverage, plans and health savings accounts (HSAs) to maximize their physical, mental and financial well-being.